Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENERATION HD1: Tominersen in manifest Huntington's disease
NCT03761849Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2019
- Primary completion
- Mar 2022
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 18
01
Overview
A Phase 3 trial of tominersen in Huntington's disease (HD), sponsored by Roche. Started Jan 2019; status: completed.
02
Drugs
tominersen
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT03761849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03761849.